Ginkgo Bioworks Intrinsic Stock Value – Ginkgo Bioworks and Biogen Successfully Complete Gene Therapy Program

☀️Trending News

Ginkgo Bioworks ($NYSE:DNA), a leader in the synthetic biology space, has announced the successful completion of a gene therapy program with Biogen. The company designs and engineers custom microbes for partners across multiple industries, including agriculture, pharmaceuticals, and food & beverage, among others. Through its proprietary process of automating organism design, Ginkgo Bioworks hopes to revolutionize how biology is engineered and manufactured. The collaboration with Biogen is part of Ginkgo Bioworks’ efforts to create a new gene therapy platform that has the potential to treat a range of genetic diseases.

The program sought to develop gene therapies for neurological and neuromuscular disorders using Ginkgo’s proprietary DNA writing platform. The partnership between Ginkgo Bioworks and Biogen has been highly successful, leading to the development of multiple preclinical candidates in just two years. The success of this project speaks to Ginkgo Bioworks’ ability to rapidly develop gene therapies that could potentially have life-changing effects.

Share Price

On Thursday, Ginkgo Bioworks and Biogen announced the successful completion of their gene therapy program. The news sent GINKGO BIOWORKS stock soaring, opening at $1.6 and closing at the same price, up by 1.3%. This is an increase from the previous closing price of 1.5.

The collaboration between the two companies bodes well for both, and shows promise for future gene therapy treatments. It is clear that Ginkgo Bioworks is poised to benefit from the recent success and is likely to see further increases in stock prices in the not so distant future. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Ginkgo Bioworks. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Ginkgo Bioworks. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Ginkgo Bioworks. More…

Key Ratios Snapshot

Some of the financial key ratios for Ginkgo Bioworks are shown below. More…

Analysis – Ginkgo Bioworks Intrinsic Stock Value

GoodWhale has conducted an analysis of GINKGO BIOWORKS‘s wellbeing and determined that the fair value of the company’s share is around $3.9. This figure was calculated using our proprietary Valuation Line method. Currently, GINKGO BIOWORKS stock is traded at $1.6, which represents a significant undervaluation of 58.9%. We believe that investors should consider the potential upside of GINKGO BIOWORKS and consider taking advantage of this opportunity. More…

Peers

The competition among Ginkgo Bioworks Holdings Inc and its competitors is fierce. Abivax SA, Atreca Inc, and Kiromic BioPharma Inc are all vying for a piece of the pie in the biotechnology industry. Ginkgo Bioworks Holdings Inc has a strong hold on the market, but its competitors are quickly catching up.

– Abivax SA ($OTCPK:AAVXF)

Abivax SA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies with the potential to transform the lives of patients suffering from chronic inflammatory diseases and cancer. The Company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.

Abivax SA has a market cap of 178.76M as of 2022, a Return on Equity of -132.3%. The company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.

– Atreca Inc ($NASDAQ:BCEL)

Atreca Inc is a biopharmaceutical company that focuses on the development of antibody-based therapeutics to treat cancer. As of 2022, its market cap is 59.43 million and its ROE is -86.67%. The company’s focus on developing cancer treatments makes it a risky investment, but its potential rewards are high.

– Kiromic BioPharma Inc ($NASDAQ:KRBP)

Kiromic BioPharma Inc is a clinical stage biopharmaceutical company that uses proprietary gene editing platform to develop cancer therapies. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.

Kiromic has a market cap of 5.32M as of 2022 and a Return on Equity of -127.9%. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.

Summary

Ginkgo Bioworks is a leader in the field of synthetic biology, and they recently achieved a major milestone with Biogen. They successfully completed a gene therapy program, which could open up a new era of treatments for a variety of diseases. This could be highly lucrative for investors, as the technology could revolutionize the medical sector.

Ginkgo Bioworks has also developed a platform that utilizes automated hardware, software, and biology to engineer cells and optimize them for different applications. Their technology has the potential to help solve some of the world’s most pressing challenges, such as renewable energies and food production.